Cerebral small vessel disease also tied to risk for extracranial bleeding<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Jan. 8, 2024 (HealthDay News) — Cerebral small vessel disease (SVD) predicts intracranial hemorrhage for patients with cerebrovascular or cardiovascular disease taking antithrombotic therapy, according to a study published online Dec. 25 in the\u00a0Annals of Neurology<\/em>.<\/p>\n Kanta Tanaka, M.D., Ph.D., from the National Cerebral and Cardiovascular Center in Suita, Japan, and colleagues determined the excess risk for antithrombotic-related bleeding due to cerebral SVD burden. The analysis included 5,250 patients (median age, 73\u00e2\u0080\u0089years) with cerebrovascular or cardiovascular disease taking oral antithrombotic agents across Japan between 2016 and 2019.<\/p>\n The researchers found that the incidence rate of major bleeding was 0.39 per 100 person-years with SVD score 0; 0.56 with SVD score 1; 0.91 with SVD score 2; 1.35 with SVD score 3; and 2.24 with SVD score 4. For intracranial hemorrhage, the incidence rates were 0.11, 0.33, 0.58, 0.99, and 1.06, respectively, across SVD scores; the corresponding ischemic event incidence rates were 1.82, 2.27, 3.04, 3.91, and 4.07. There was a significantly elevated risk seen for extracranial major bleeding and gastrointestinal bleeding for SVD score 4 versus 0.<\/p>\n “Total SVD score was predictive for intracranial hemorrhage and probably for extracranial bleeding, suggesting the broader clinical relevance of cerebral SVD as a marker for safe implementation of antithrombotic therapy,” the authors write.<\/p>\n Abstract\/Full Text\u00a0(subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n